DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(12 sites)

China

Beijing Cancer Hospital, Beijing, Beijing Municipality

The First Affiliated Hospital of Xiamen University, Xiamen, Fujian

Harbin Medical University Cancer Hospital, Harbin, Heilongjiang

The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan

Hubei Cancer Hospital, Wuhan, Hubei

Hunan Cancer Hospital, Changsha, Hunan

Xuzhou Central Hospital, Xuzhou, Jiangsu

Shandong Cancer Hospital, Jinan, Shandong

The Affiliated Hospital of Qingdao University, Qingdao, Shandong

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai Municipality

West China Hospital of Sichuan University, Chengdu, Sichuan

Yunnan Cancer Hospital, Kunming, Yunnan